Friday, May 17, 2013

Acupuncture and Major Depressive Disorder


S.S. and colleagues presented a study on acupuncture in patients with major depressive disorder: “A 6-week randomized controlled trial with 4-week follow-up of acupuncture combined with paroxetine in patients with major depressive disorder.” Link: http://www.ncbi.nlm.nih.gov/pubmed/23498306  

The authors start: “Acupuncture possesses the antidepressant potential.” That’s an unproven statement! They came to this conclusion: “Our study indicates that acupuncture can accelerate the clinical response to selective serotonin reuptake inhibitors (SSRIs) and prevent the aggravation of depression. Electrical acupuncture may have a long-lasting enhancement of the antidepressant effects (Trial Registration: ChiCTR-TRC-08000278).” No, that’s what the authors want and not what the study tells. The study lacks a real control group. It only tells that if you give special attention (18 sessions of manual acupuncture or electrical acupuncture) on top of paroxetine, you can “accelerate the clinical response to selective serotonin reuptake inhibitors (SSRIs) and prevent the aggravation of depression.” You might even do more – instead of 18 acupuncture sessions you can try 18 individual sessions with a psychologist.

FreitagsGedichte



Tage

Manche Tage
Nimmt man besser an die Leine
Und muß sie hinter sich herZiehen

Andere Tage
Die hüpfen fröhlich um dich herum
Und reißen dich mit


Das Salz der Stille

WaldWasser
Am frühen Morgen
Zu Nebel verDunstet
Um dem Grün einen Hauch
Von melancholischem Grau zu gewähren

TränenWasser
VerDunstet im AlltagsGrau

TintenWasser
In trockenen StudierStuben verDunstet
Und doch bleibt etwas zurück


Die Esche

Eigentlich ist die Esche kein besonders schöner Baum; kein Baum für Dichter.

Aber im ZusammenSpiel der Färbung des Herbstes und der Spiegelung des blauen Himmels im munter hüpfenden Wasser wurde die Esche doch geadelt.

Als ich genug vor dem Baum herumgelungert hatte, schrieb ich doch kein Gedicht.


In Kenntnis der Nacht

Ich kann die Nacht hören
Wie sie zu schweigen versucht
Ich rieche sie
Und jede AusDünstung des Todes

Versuche nicht
Mit Lampen
Die Schwärze zu durchDringen

Ich kenne die Nacht
Ihre verSchwiegenen TreffPunkte



Thursday, May 16, 2013

Carpe Diem Haiku Kyoshi Takahama's 'the Night of Spring'




Warm spring night, cozy
Leaning the head on a thigh
Looking at the moon

Catch the moon quickly
As the spring night will end soon
And your dreams vanish




http://chevrefeuillescarpediem.blogspot.de/


Krzyszof Kokot and Robert Kania from http://europeankukai.blogspot.com invite for a haiku competition. Topic: SUMMER (the word "summer" is not required but should be clearly imaged). Any unpublished haiku in English. Period for submission: Saturday, May 18 - Saturday, June 8, 2013.
Please look up the details at European Kukai. Address for all Kukai correspondence: european.kukai@gmail.com



Tuesday, May 14, 2013

Carpe Diem Haiku The Hermit



A new spring reaches
Into the dark cave to touch
The seeking hermit




The hermit
Not seeking company
Is well known




Retreating from men
The hermit has left one step
Letting go himself

Only the hermit
Knows what lies behind the light
More light or darkness


http://chevrefeuillescarpediem.blogspot.de/


Krzyszof Kokot and Robert Kania from http://europeankukai.blogspot.com  invite for a haiku competition. Topic: SUMMER (the word "summer" is not required but should be clearly imaged). Any unpublished haiku in English. Period for submission: Saturday, May 18 - Saturday, June 8, 2013.
Please look up the details at European Kukai. Address for all Kukai correspondence: european.kukai@gmail.com  



EULAR 2013 Meeting in Madrids



This is the list of topics, I'm interested in. I'll look at all of the posters and try to be in as many of the sessions duiscussing these topics. More information on the drugs/topics look for the links.

ALX-0061
Anti-IL-6 Receptor Nanobody (ALX-0061) – anything new?

Anakinra - IL-1Ra-Receptor antagonist
New fields of action?
Link to the EULAR evaluation: http://rheumatologe.blogspot.de/2012/07/anakinra-and-pseudogout-calcium.html

Ankylosing Spondylitis
New drugs? New developments?
Link to the EULAR 2012 blog post: http://rheumatologe.blogspot.de/2012/07/ankylosing-spondylitis-refractory-to.html  

Anti-CD20 Monoclonal Antibody (like Rituximab)
Ocrelizumab, ocaratuzumab, which will be looked at below.
More information on other agents at: http://rheumatologe.blogspot.de/2012/06/anti-cd-20-monoclonal-antibody.html  

Anti-CD-40 Monoclonal Antibody
There´s no anti-CD40 agent, but my guess is that there will be. So I keep it on the list. – Well let’s see if EULAR has something this year.
Link to preliminaries at the EULAR 2012: http://rheumatologe.blogspot.de/2012/08/targeting-cd-40-preliminaries-at-eular.html

ARRY-371797 / ARRY-797
Still sceptic!

ASP015K
"An oral Janus kinase (JAK) inhibitor with selectivity for JAK1/3.

Baricitinib
Baricitinib (also known as INCB28050, LY3009104) is an oral JAK1 and JAK2 inhibitor.
For results presented at EULAR 2012 look here: http://rheumatologe.blogspot.de/2012/06/baricitinib-ly3009104-at-eular-2012-in.html

Belimumab
"Belimumab is a recombinant, human Ig-G1 monoclonal antibody that binds and antagonizes the biological activity of soluble B-lymphocyte stimulator protein."  

Biosimilars
Still problems getting them to market approval.

Brodalumab
Brodalumab targets the interleukin-17 (IL-17) and is therefore much like ixekizumab, see below. How about PsA?

BT061
Target is CD4. Maybe we shall see some preliminary results. – If there isn’t any new data, I’ll erase this one from my list. Though: Estimated Study Completion Date: December 2013. http://clinicaltrials.gov/ct2/show/NCT01481493  
Mabe we shall see some preliminary results.

Canakinumab (ACZ885)
More on orphan diseases?

CCX354-C
CCX354-C should come up with some new data.
For EULAR 2012 look at: http://rheumatologe.blogspot.de/2012/07/ccx-354-c-at-eular-2012.html

Cetrorelix
Cetrorelix is a gonadotropin-releasing hormone antagonist (GnRH antagonist). http://rheumatologe.blogspot.de/2012/07/cetrorelix-at-eular-2012.html
http://rheumatologe.blogspot.de/2012/12/cetrorelix-at-acr-2012-in-washington.html

Dekavil
Dekavil - fibronectin-A-chain connected to IL-10. Still progressing slowly?
http://rheumatologe.blogspot.de/2012/07/dekavil-at-eular-2012.html
http://rheumatologe.blogspot.de/2012/12/dekavil-at-acr-2012-in-washington.html

Fibromyalgia
Fibromyalgia – anything on the hype of “change of paradigm”?

Fostamatinib
Concerning fostamatinib (a SYK inhibitor) it’s getting tight? http://rheumatologe.blogspot.de/2012/07/fostamatinib-at-eular-2012.html  
http://rheumatologe.blogspot.de/2012/12/fostamatinib-at-acr-2012-in-washington.html

GLPG0634
Selective JAK1 inhibitor. Better than tofacitinib or not as efficacious?
http://rheumatologe.blogspot.de/2012/12/glpg0634-at-acr-2012-in-washington.html

Iguratimod
Iguratimod, a new DMARD, is under way from Japan. Maybe something new presented in Europe?! http://rheumatologe.blogspot.de/2012/06/iguratimod-at-eular-2012.html

Ixekizumab
Ixekizumab targets the interleukin-17 (IL-17) and is also known as LY2439821. It has been introduced at the ACR 2011 in Chicago: http://rheumatologe.blogspot.de/2011/11/ly2439821-anti-il-17-monoclonal.html.
But after this introduction - no further use. It should be an interesting target (maybe more in PsA), but perhaps ixekizumab is failing to hit the target.

Mavrilimumab
Mavrilimumab is a human MAB for the treatment of rheumatoid arthritis. It targets the GMCSF receptor and alpha-chain. http://rheumatologe.blogspot.de/2012/07/mavrilimumab-at-eular-2012.html  
GMCSF? I'm very sceptical.

Modified release prednisone
On modified release prednisone: http://rheumatologe.blogspot.de/2012/06/modified-release-prednisone.html.
To sum it up: I'm even more sceptic about modified release prednisone after the ACR 2012! Will this scepticism be reduced at the EULAR?

MOR103
Target GMCSF, there had been some interesting data, but only published by MorphoSys: http://www.morphosys.com/pressrelease/morphosyss-mor103-antibody-demonstrates-excellent-safety-and-efficacy-rheumatoid-arthritis-patients.
There has been a late breaking poster at the ACR on MOR103. Link:  http://rheumatologe.blogspot.de/2012/12/mor103-at-acr-2012-in-washington.html
I think the paper left open lots of questions.

NKG2a
There hasn't been too much on NKG2A / NNC141-0100 both at the EULAR 2012 and the ACR 2012. Link: http://rheumatologe.blogspot.de/2012/07/nkg2a-nnc141-0100-at-eular-2012.html and http://rheumatologe.blogspot.de/2012/12/nkg2a-at-acr-2012-in-washington.html  
I hope to see more.

NNC0114-0005
NNC0114-0005 is a recombinant anti-IL-21 monoclonal antibody. Link: http://rheumatologe.blogspot.de/2012/12/nnc0114-0005-at-acr-2012-in-washington.html  

NNC0109-0012
"NNC0109-0012 (anti-IL-20 mAb) is a novel human monoclonal IgG4 antibody which binds to and neutralizes the activity of IL-20." And the word still ring in my ear: "The data from this trial support further clinical development of NNC0109-0012 (anti-IL-20 mAb) in RA." Link to more information: http://rheumatologe.blogspot.de/2012/12/nnc0109-0012-at-acr-2012-in-washington.html  
How much is there to be expected within half a year?

Ocaratuzumab
Ocaratuzumab is a Fc- and Fab engineered anti-CD20 antibody, which showed rapid and sustained depletion of circulating B-cells in rheumatoid arthritis patients (No. 835). A. O'Reilly and colleagues also discussed the possibility of using ocaratuzumab subcutaneously.
Link to more information: http://rheumatologe.blogspot.de/2012/12/ocaratuzumab-at-acr-2012-in-washington.html  
Will s.c. cause problems because of missed follow-ups?

Olokizumab
Olokizumab targets interleukin-6 (IL-6). So it would be much like tocilizumab (Actemra). I haven’t seen any study at the EULAR 2012 meeting in Berlin. But I have seen some results on olokizumab at the ACR 2012. Link to more information: http://rheumatologe.blogspot.de/2012/12/olokizumab-at-acr-2012-in-washington.html  
If there won't be any results ... maybe it's going to be abandoned.

Ozoralizumab (ATN-103)
R. M. Fleischmann and colleagues presented: "A Novel Individualized Treatment Approach in Open-Label Extension Study of Ozoralizumab (ATN-103) in Subjects with Rheumatoid Arthritis On a Background of Methotrexate" (No. 1311). "Ozoralizumab (ATN-103), a novel TNF-inhibitor, is a trivalent, bispecific Nanobody (R) that potently neutralises TNF ..." Results: " ... EULAR good/moderate response rate was 97% ...". Conclusions: " ... This treatment approach could prove beneficial to patients and minimize treatment costs."
Link: http://rheumatologe.blogspot.de/2012/12/ozoralizumab-atn-103-at-acr-2012-in.html
If I hear nano, I think of hype; but maybe I'm too sceptical.

Pateclizumab
Pateclizumab is an anti-Lymphotoxin-alpha Monoclonal Antibody. http://rheumatologe.blogspot.de/2012/06/pateclizumab-anti-lymphotoxin-alpha.html
Nothing at the ACR 2012, but I´ll wait until the EULAR 2013 before I´ll erase pateclizumab from my list of interests.
Anti-Lymphotoxin might not work alone. So dropping the development of a new drug now and use it in the future in some combination would be still an option.

Pioglitazone
Pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, used in diabetes, has been tested in rheumatoid arthritis: "A Proof-of-Concept Randomized Controlled Trial" by M. J. Ormseth and colleagues (No. 832). Pioglitazone "modestly reduces RA disease activity measured by DAS28 CRP and CRP levels". If you want more, then here's the link: http://rheumatologe.blogspot.de/2012/12/pioglitazone-at-acr-2012-in-washington.html
Modestly ... honestly I doubt that pioglitazone will be a success.

PRTX-100 (Staphylococcal Protein A)
E. Bernton et al. presented: "A Phase 1, Randomized, Double-Blind, Placebo-Controlled Multiple-Dose Study of Intravenous Staphylococcal Protein A in Patients with Active Rheumatoid Arthritis On Methotrexate: Safety, Pharmacokinetics and Efficacy" No. 833). As I had been part in testing immunoadsorption, I´m not too confident in PRTX-100. But it´s still too early for skepticism.You find more here: http://rheumatologe.blogspot.de/2012/12/prtx-100-staphylococcal-protein-a.html
The EULAR might still be too early.

Psoriatic Arthritis
Non-anti-TNF Biologics in Psoriatic Arthritis at EULAR 2011. http://rheumatologe.blogspot.de/2012/07/non-anti-tnf-biologics-in-psoriatic.html. I hope for new results on new drugs as therapy for psoriatic arthritis still lags behind. Maybe Brodalumab.
I've found some data on apremilast in psoriatic arthritis:
http://rheumatologe.blogspot.de/2012/12/psoriatic-arthritis-at-acr-2012-in.html

Ruxolitinib
Ruxolitinib is a JAK1/JAK2 inhibitor, which could be useful to treat rheumatoid arthritis. Nothing new at the EULAR 2012 and the ACR 2012. But there has been a study mentioning the drug (No. 1807). http://rheumatologe.blogspot.de/2012/12/ruxolitinib-at-acr-2012-in-washington.html
Time is pressing, ruxolitinib!

Sarilumab
Sarilumab is another anti-IL-6 monoclonal antibody. http://rheumatologe.blogspot.de/2012/06/sarilumab-news-from-eular-2012.html  
At the ACR 2012 sarilumab failed to present the final results of the phase 2 study and nothing on a phase 3 study. And here are the details:
http://rheumatologe.blogspot.de/2012/12/sarilumab-at-acr-2012-in-washington.html
So the 2013 meetings might be cricial.

SBI-087
SBI-087 is a SMIP (= small molecule immune pharmaceutical) binding to CD-20 http://rheumatologe.blogspot.de/2012/07/sbi-087-at-eular-2012.html  
Nothing at the ACR 2012. If there isn´t anything at the EULAR2013, I´ll erase this one, too.

Secukinumab
Secukinumab is an Anti-Il17a Monoclonal Antibody. http://rheumatologe.blogspot.de/2012/06/secukinumab-anti-il17a-monoclonal.html  
There have been two studies at the ACR 2012: http://rheumatologe.blogspot.de/2012/12/secukinumab-at-acr-2012-in-washington.html  
I'll have to check results against brodalumab.

Small molecules / protein kinase inhibitors
Safety of different small molecules / protein kinase inhibitors http://rheumatologe.blogspot.de/2012/06/safety-of-different-small-molecules.html  
I'll have a look at other PK inhibitors as well, which aren't mentioned or which surface at the EULAR meeting.

Synavive
Synavive, a combination of 2 mgs of prednisolone and 200 mgs of dipyramidole: http://rheumatologe.blogspot.de/2012/07/synavive-crx-102-at-eular-2012.html.
A new idea, what how much benefit for our patients? As there hasn't been anythin at the ACR 2012, I might erase this one, too.

Tabalumab
Tabalumab is an anti-BAFF Monoclonal Antibody. http://rheumatologe.blogspot.de/2012/06/tabalumab-ly2127399-anti-baff.html. I'm very skeptical about benefits in RA. Here are the details:
http://rheumatologe.blogspot.de/2012/12/tabalumab-at-acr-2012-in-washington.html 
I might erase this MAB, too.

Tocilizumab
There might be something on tocilizumab and amyloidosis. http://rheumatologe.blogspot.de/2012/06/tocilizumab-at-eular-2012.html.
How about subcutaneous tocilizumab? When will it be available?

Tofacitinib
The oral JAK 1 and 3 inhibitor tofacitinib (CP-690,550) had already attracted most attention at the EULAR 2012. See here: http://rheumatologe.blogspot.de/2012/07/tofacitinib-oral-jak-inhibitor-at-eular.html.
At the ACR 2012 the real hit has been: tofacitinib has been approved by the FDA, with a black box warning on opportunistic infections, tuberculosis, cancers, lymphoma, and is available on the US market as Xeljanz. EMA approval has been postponed. See: http://rheumatologe.blogspot.de/2013/04/xeljanz-tofacitinib-and-negative.html 

Ustekinumab
Ustekinumab and other options in psoriatic arthritis. http://rheumatologe.blogspot.de/2012/07/ustekinumab-and-other-options-in.html.
Quite lot discussion you'll find here: http://rheumatologe.blogspot.de/2012/12/ustekinumab-at-acr-2012-in-washington.html
We have been discussing ustekinumab in a circle of rheumatologists at "Immunology & more", first impression is that it works better on the skin than on the joints. So, I'll be looking, if this hypothesis is addressed in any of the studies.

Veltuzumab
Target CD20, VELVET, a Dose Range Finding Trial of Veltuzumab in Subjects With Moderate to Severe Rheumatoid Arthritis – the study is ongoing. Please check: http://rheumatologe.blogspot.de/2012/06/anti-cd-20-monoclonal-antibody.html  
If you wait for results you have to join me. Nothing new elucidated at the ACR 2012 in Washington. If there isn´t some development until EULAR 2013, I´ll erase this one.

VX-509
A JAK 3 inhibitor. I'd give some time.

VX-702
There hasn't been anything new on VX-702, a novel p38 MAPK inhibitor, at the 2012 meetings. If there isn´t some development until EULAR 2013, I´ll erase this one, too. I'm not convinced that p38 MAPK is a good target.


Monday, May 13, 2013

@Pontifex and @justinbieber on Twitter



I could have taken other twitter accounts with mass following, but mass inevitably leads to @Pontifex (as he holds mass) and @justinbieber (as he accumulated the largest mass of followers - 39,038,384).

If we compare similarities and dissimilarities between the two, we might come closer to understand phenomena created by twitter.

An old man versus a very young man. The comparison won't bring us any further.

A learned man versus a not so well educated man. Has this any impact on followers? Maybe on the kind of follower, each one attracts. Maybe on the tweets they write.

Do they write their own tweets? It's unclear. I doubt it. Both have entourages that will eagerly fulfill this task. Mass following means that there will hardly be any account to account twittering as "mentioning" of both will be overfloaded with tweets. As @Pontifex follows no one except himself, his timeline will be useless. As @justinbieber is following 122,874 is also useless as it will be overflowing. On May 11th @justinbieber tweeted: “God is great” and “Live life full”. @Pontifex tweeted on May 10th: “The Holy Spirit brings to our hearts a most precious gift: profound trust in God’s love and mercy.” Maybe they tweet sometimes on their own, but they don’t engage in bidirectional communication. Or they might do by PM.

There are quite a lot of retweets by people who hardly reach as many people as @Pontifex and @justinbieber. So it’s open to discussion, why they retweet. Maybe it’s something like a fav.

The idea of @Pontifex to use twitter as a means to spread the gospel is a good one. But is this kind of twittering with a tweet per day more than having a rip off calendar with a quote a day? Hardly! Or is it that people might attribute that the pope himself is tweeting to each individual? That would be fatal!

@justinbieber uses his account to thank his fans, to spread pictures, to announce tour details, and congratulates his mother on Mother’s. Some people might say: “Ain’t he sweet?!” But he uses twitter successfully for commercial purposes. Nothing wrong with this side of twitter.

Maybe we'll see a social media @Pontifex soon. There are dangers in it, which he circumvents at the moment. He likes to talk to people, but would he like to answer to tweets? How could he restrict it without only following the Roman curia?

Twitter has started with very few gadgets and limitations. There is the 140 character restriction, which is sufficient for most purposes. So one phenomenon is self organisation. Groups or circles and their members will organize themselves. That means lots of freedom.

Links can be multiplied within a short time. That means certain news will spread at breathtaking speed. But there's also the danger that such a phenomenon could be misused. Both @Pontifex and @justinbieber won't have this problem as long as it concerns their own tweets. There's a caveat, however. As long as their accounts aren't hacked. Twitter accounts get hacked as twitterworld isn't better than the real world. It could be, it should be, but it isn't.
06.06.2013
‏@Pontifex_de Die Schöpfung zu hüten ist nicht bloß ein Aufruf Gottes zu Beginn der Geschichte, sondern geht jeden von uns an und ist Teil seines Plans.
@Rheumatologe "Die Schöpfung zu hüten" - wer hat denn das übersetzt? Schafe hütet man, die Schöpfung sollten wir bewahren.
The corresponding tweet in English is:
@Pontifex Care of creation is not just something God spoke of at the dawn of history: he entrusts it to each of us as part of his plan.
@Rheumatologe Who translated "To shepherd the creation? One shepherds sheep, we should care for the creation.

Friday, May 10, 2013

Radonstollen



Radonstollen oder Heilstollen werden besonders in Österreich und Deutschland immer noch betrieben. Sie stammen aus einer Zeit, in denen die Medizin den entzündlich-rheumatischen Erkrankungen nicht viel entgegenzusetzen hatten und solche Erkrankungen häufig in den Rollstuhl führten. Aber ist diese Therapieform noch zeitgemäß?
Osteoporose, Fibromyalgie, degenerative und entzündlich-rheumatische Erkrankungen des Bewegungsapparates, ja auch Gicht, alles soll besser werden. Schlecht heilende Wunden, Sklerodermie, Heuschnupfen, Asthma usw. ebenso. Das zeigt, wie unspezifisch die Therapie mit Radon ist. Und - ist es überhaupt das Radon, das da wirkt?
Man geht davon aus, dass die Radioaktivität eine Wirksamkeit entfalte. Das ist aber Glaube an Magie, denn sonst müßten Tschernobyl oder Fukushima überlaufen sein. Und wenn es der ollen an sich ist, warum dann nicht Einfahrten in stillgelegte Salzbergwerke oder Steinkohlebergwerke im Ruhrgebiet?
An folgender Veröffentlichung kann man das gut erklären, was Stephen Bennett als "Quack Science" bezeichnet.
Moder, A., Hufnagl, C., Lind-Albrecht, G., Hitzl, W., Hartl, A., Jakab, M. and Ritter, M. (2010) ‘Effect of combined Low-Dose Radon- and Hyperthermia Treatment (LDRnHT) of patients with ankylosing spondylitis on serum levels of cytokines and bone metabolism markers: a pilot study’, Int. J. Low Radiation, Vol. 7, No. 6, pp.423–435.
In der Zusammenfassung (Abstract) findet sich die folgende Passage:
"We therefore performed a study on 33 AS patients to investigate the effect of LDRnHT on serum levels of bone metabolism markers and cytokines involved in chronic inflammatory disorders. It is shown that TGF-β1, TNF-α, IL-6, OPG and RANKL levels significantly increased after LDRnHT and that the ratio of OPG over RANKL is significantly elevated."
Da wurden also Zytokine (bestimmte Botenstoffe) gemessen und die hatten sich verändert. Sehen wir einmal über die geringe Zahl von Patienten hinweg. Die Studie hat keine Kontrollgruppe. Sämtliche Veränderungen werden auf den Heilstollen zurückgeführt und nicht auf die z.B. gleichzeitig durchgeführt Rehabilitationsbehandlung. Es hätte sich leicht eine Kontrollgruppe finden lassen. Die Ergebnisse sind wohlgemerkt korrekt erhoben worden, aber sie sagen so überhaupt nichts über die Behandlung im Heilstollen aus.
Eine interessante Beobachtung ist die Zahl sogenannter Pilotstudien, denen dann keine weiteren Studien gefolgt sind. In einer Studie von A. Franke et al. wurde sieben Jahre lang gescreent, also ca. 25 Patienten pro Jahr (DOI 10.1007/s00296-006-293-6). Aber vielleicht müssen wir nur genügend lange warten.
Anläßlich der "Jahrestagung der Österreichischen Gesellschaft für Rheumatologie und Rehabilitation" am 24. und 25. November 2006 in Wien wurde eine Pilotstudie zu "Fibromyalgie – Schmerz und Erschöpfung / Verlauf nach Gasteiner Heilstollentherapie im Rahmen der Kurbehandlung" vorgestellt. 21 Patienten wurden im Rahmen eines multimodalen Therapiekonzepts untersucht, das neben den Stolleneinfahrten auch aktivierende Elemente und Schulungsmaßnahmen beinhalteten. "Der Rücklauf auf die Nachbefragung bei T3 (4 Monate nach der Kur) betrug 76 % (16 von 21 Patienten)." Zu diesem Zeitpunkt erfaßt man einen Effekt, den ich den Kegeltoureffekt nenne. Da ist auf jeden Fall eine Besserung festzustellen.
Die Exposition einer Radonstollenkur wurde mit 1,8 mSv angegeben, wobei die mittlere natürliche Strahlenbelastung pro Jahr 2,4 mSv beträgt [G. Lind-Albrecht und S. Rotheimer-Hering in Journal für Mineralstoffwechsel 2005; 12 (4)]; das sind immerhin 75% der jährlichen natürliche Exposition, die noch dazukommt. Nach Berechnungen der Betreiber besteht kein erhöhtes Risiko etwa für die Entwicklung von Krebs. Trotzdem wird vor Radon gewarnt.
Warum nicht in den Keller gehen, dort seine Radon-Dosis abbekommen und man ist geheilt?
Nein! Ich halte die Therapie im Radonstollen für überholt. Es sind sicherlich Effekte vorhanden, die aber nicht unbedingt dem Radon und seiner Radioaktivität zuzuordnen sind. Deshalb sollte zugunsten von effektiveren Therapien, die mittlerweile existieren, und zur Reduktion der Strahlenexposition darauf verzichtet werden. Ich rate von der Heilstollentherapie ab.

Zur Gefahr von Radon: http://www.test.de/Schutz-vor-Radon-Gefahr-aus-dem-Boden-1423844-0/, oder hier ein Artikel in Der Welt: http://www.welt.de/wissenschaft/umwelt/article6704963/Radon-die-vernachlaessigte-Gefahr-aus-dem-Boden.html

Link zum Blogpost vom letzten Jahr zum Thema Radonstollen: http://rheumatologe.blogspot.de/2012/07/radonstollen-therapie-bei-rheumatischen.html